Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

118.31 +5.18 (+4.57%)
Streaming Delayed Price Updated: 2:08 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
Via Benzinga
Why Novavax Stock Fell Today
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Wednesday amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency Use Authorization for the company's updated... 
Via Benzinga
Exposures COVID-19 Product Safety
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 
Via Benzinga
Short Sellers Are Betting Against Novavax (NVAX) Stock
Shorts are betting no one will want Novavax's Covid-19 vaccine, but the pandemic is not yet over, and NVAX stock is cheap. 
Via InvestorPlace
Exposures COVID-19
Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna
The company can now join Pfizer and Moderna in launching an updated booster in the U.S. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Novavax Stock Soars On FDA Clearance For Updated Covid-19 Shot: What's Going On?
Novavax Inc (NASDAQ: NVAX) shares are surging Tuesday afternoon after the U.S. 
Via Benzinga
Exposures COVID-19 Product Safety
Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19
Discover the remarkable journey of Nobel Prize laureates Kariko and Weissman, who transformed medicine with mRNA vaccines, and the financial impact on Moderna and Pfizer stocks. 
Via Benzinga
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
Analysts like these stocks for very good reasons. 
Via The Motley Fool
Why Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle. 
Via The Motley Fool
Exposures COVID-19
Why CureVac Stock Plunged Today
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech. 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused... 
Via Benzinga
DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer
The deal keeps Ginkgo alive, but its business model of becoming the "Apple Store of Biotech" remains unproven. DNA stock jumped overnight. 
Via InvestorPlace
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
As the U.S. 
Via Benzinga
Exposures COVID-19
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
All three companies should benefit from increased COVID-19 booster sales. 
Via The Motley Fool
Exposures COVID-19
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
From BioNTech SE
Via GlobeNewswire
More Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma Alone
New COVID-19 boosters have been approved by the U.S. FDA in the fight against new variants. A new survey showed how likely people are to get new boosters and if they will have their children get... 
Via Benzinga
Exposures COVID-19 Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now. 
Via InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
Benzinga 
Via Benzinga
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
The U.S. 
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry
On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) that targets only the... 
Via Benzinga
Exposures COVID-19
Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant
Pirola has about 30 mutations compared with previous omicron versions of the virus. 
Via Investor's Business Daily
Exposures COVID-19
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
Exposures COVID-19 Product Safety
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
Exposures COVID-19
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
Jeff Bezos Vs. Elon Musk Space Contract Lawsuit, Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations, Tesla Rival XPeng's August Deliveries Zooms 43%: Today's Top Stories
Tech Crunch 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.